The GLP-1 Shortage Is Over. Mass-Market Compounding Should Be, Too
The market for copycat versions remains substantial.
By one estimate, roughly 1.5 million Americans take compounded GLP-1s.
That's cause for concern.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.forbes.com — the content belongs to Forbes.
